Comments
The final hearing on drug-maker Novartis’ petition challenging the rejection of its patent application for cancer drug Glivec has been adjourned to late next month.
“Following the unavailability of the Senior Counsel representing Novartis, a joint request for adjournment was made to the Bench. The request was accepted and the case is now listed for August 22,” a Novartis statement said.
The Swiss drug-major Novartis AG is challenging the rejection of its patent application (in 2006) for the beta-crystalline form of imatinib mesylate (sold under the brandname Glivec).
The high-profile case will set a benchmark as it further clarifies the implementation of the amended Indian Patents Acts – particularly on issues regarding the interpretation and assessment of efficacy of the medicine seeking a product patent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.